Consensus
The community is moderately leaning bullish on Novartis at 61%, based on 8 forecasts. Forecasters are in moderate agreement.
Resolves YES if Novartis's price 180 days out is above its baseline price.
Share your read on this question — the best forecasters show their work.
See the whole nvs discussion →